

Lilotomab

Cat. No.:	HY-P99707
CAS No.:	1453362-55-4
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Lilotomab (HH1) is a murine anti-CD37 monoclonal antibody. Lilotomab reduces clonogenic survival. Lilotomab shows anti-tumor activity ^[1] .									
IC₅₀ & Target	CD37 ^[1]									
In Vitro	<p>Lilotomab (0-40 µg/mL; 12 days) reduces the clonogenic survival of DOHH2 and Ramos cells^[1]. Lilotomab (40 µg/mL; 18 h) induces slight apoptosis in DOHH2 cells^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Apoptosis Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Ramos, DOHH2, Rec-1 cells</td> </tr> <tr> <td>Concentration:</td> <td>40 µg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>18 h</td> </tr> <tr> <td>Result:</td> <td>Induced apoptosis in DOHH2 cells.</td> </tr> </table>		Cell Line:	Ramos, DOHH2, Rec-1 cells	Concentration:	40 µg/mL	Incubation Time:	18 h	Result:	Induced apoptosis in DOHH2 cells.
Cell Line:	Ramos, DOHH2, Rec-1 cells									
Concentration:	40 µg/mL									
Incubation Time:	18 h									
Result:	Induced apoptosis in DOHH2 cells.									
In Vivo	<p>Lilotomab (0.5 mg/kg; i.v.; once) inhibits tumor growth in mice^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>SCID mice (DOHH2 cell xenografts)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.5 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>i.v.; once</td> </tr> <tr> <td>Result:</td> <td>Inhibited tumor growth and increased mouse survival.</td> </tr> </table>		Animal Model:	SCID mice (DOHH2 cell xenografts) ^[1]	Dosage:	0.5 mg/kg	Administration:	i.v.; once	Result:	Inhibited tumor growth and increased mouse survival.
Animal Model:	SCID mice (DOHH2 cell xenografts) ^[1]									
Dosage:	0.5 mg/kg									
Administration:	i.v.; once									
Result:	Inhibited tumor growth and increased mouse survival.									

REFERENCES

[1]. Malenge MM, et al. 177Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma. J Nucl Med. 2020

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA